Ascend Advanced Therapies

At Ascend Gene & Cell Therapies, we pride ourselves on being at the forefront of gene and cell therapy manufacturing and development. Our company was established with a vision to provide innovative solutions for next-generation therapeutics. With substantial funding of over $130 million, Ascend offers state-of-the-art capabilities in the production of Adeno-Associated Virus (AAV) vectors, essential for gene therapy applications that aim to treat previously untreatable conditions.

Founded in 2021, Ascend operates a Contract Development & Manufacturing Organization (CDMO) model that supports biotech clients through each phase of drug development, from preclinical stages to clinical trials and commercial production. Our headquarters in the UK includes GMP-compliant facilities in Potters Bar, and we also have research operations in the San Francisco Bay Area and a specialized team in Munich, Germany. With a dedicated team of around 120 experts, we leverage cutting-edge technology and deep industry experience to ensure that our services not only meet but exceed the operational and regulatory standards required in today's fast-evolving landscape of advanced therapies. Our commitment to quality and adaptability drives us to support biotech firms in accelerating their breakthroughs in gene therapies.